[Antitumor immunoadjuvants of microbial origin: the limitations in the immune system and microbial structure].
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D000970:Antineoplastic Agents / Q000276:immunology*; D001419:Bacteria / Q000276:immunology*; D002473:Cell Wall / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D005685:Galactans / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D010457:Peptidoglycan / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D013045:Species Specificity; D013329:Structure-Activity Relationship; D015003:Yeasts / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D005685:Galactans; D010457:Peptidoglycan; D011135:Polysaccharides, Bacterial; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C005653:arabinogalactan
Immunoadiuvanti antitumorali di origine microbica: limiti nel sistema e nella struttura.